Early Access — free while we kick the tires
EdgarHawk

KYMR Kymera Therapeutics, Inc. Insider Trading

Latest: COO Sold $1.4M of Shares · May 2026
1 filing analyzed · Latest 2026-05-27
Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling
May 2026
2026-05-27
medium
Jeremy G Chadwick Sell
Chief Operating Officer
17,184 shares
$1,373,290
@ $79.92
Significance 5/10

COO Jeremy G Chadwick sells 17,184 shares totaling $1,373,289.54 at KYMR via 10b5-1 plan

Jeremy G Chadwick, Chief Operating Officer, executed 7 separate sales totaling 17,184 shares for $1,373,289.54 between May 26 and May 27, 2026, reducing his holdings by 28.1% (from 61,202 to 44,018 shares). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. In context of the company's fundamentals—annual revenue growth of -16.7%, net income of $-69,234,000.00 (unprofitable), and a current stock price of $81.70 that is -20.7% from the 52-week high—this sale represents a substantial reduction in his concentrated position. His prior trades at this ticker show consistent 30-day and 90-day negative returns, with the most recent sales on 2026-04-15 yielding -8.7% and -10.3% respectively, and earlier sales showing 30-day losses ranging from -5.0% to -6.2%.

More Chemicals and Allied Products companies

Get alerts for KYMR

Add KYMR to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access